Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI)

Drug Discovery Today: Technologies

Volumn 10, Issue 1, 2013, Pages

  Kamel, Amin ^a   Harriman, Shawn ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CIMETIDINE; CLORGYLINE; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; ELLIPTICINE; ERYTHROMYCIN; FERROUS ION; FLUCONAZOLE; GESTODENE; INDINAVIR; INDUCIBLE NITRIC OXIDE SYNTHASE; ISONIAZID; KETOCONAZOLE; METYRAPONE; N ACETYL 1,4 BENZOQUINONE IMINE; ORPHENADRINE; PARACETAMOL; PAROXETINE; PHENACETIN; QUINIDINE; QUININE; SECOBARBITAL; TADALAFIL; TROLEANDOMYCIN; UNINDEXED DRUG;

ALKYLATION; BINDING SITE; COVALENT BOND; DRUG BINDING; DRUG BINDING SITE; DRUG METABOLISM; ELECTROPHILICITY; ENZYME ACTIVE SITE; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HUMAN; HYDROXYLATION; LIPOPHILICITY; LIVER TOXICITY; MECHANISM BASED INACTIVATION; PARKINSON DISEASE; PROTEIN MODIFICATION; REVIEW;

ANIMALS; BIOTRANSFORMATION; COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS;

EID: 84875705816     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2012.09.011     Document Type: Review

References (44)

1. A. Ayrton Role of transport proteins in drug absorption, distribution and excretion Xenobiotica 31 2001 469 497
2. Bjornsson The conduct of in vitro and in vivo drug-drug interaction studies: a perspective of the Pharmaceutical Research and Manufacturers of America Drug Metab. Dispos. 31 2003 815 832
3. M.A. Dickins Induction of cytochromes P450 Curr. Top. Med. Chem. 4 2004 1745 1766
4. M.G. Soars The pivotal role of hepatocytes in drug discovery Chem. Biol. Interact. 168 2007 2 15
5. C. Loguercio Effect of alcohol abuse and glutathione administration on the circulating levels of glutathione and on antipyrine metabolism in patients with alcoholic liver cirrhosis Scand. J. Clin. Lab. Invest. 56 1996 441 447
6. M.F. Hebert Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction Clin. Pharmacol. Ther. 52 1992 453 457
7. Lin, and Lu Inhibition and induction of cytochrome P450 and the clinical implications Clin. Pharmacokinet. 35 1998 361 390
8. C.F. Wilkinson Structure-activity relationships in the effects of 1-alkylimidazoles on microsomal oxidation in vitro and in vivo Biochem. Pharmacol. 23 1974 2377 2386
9. T.D. Rogerson Steric factors in the inhibitory interactions of imidazoles with microsomal enzymes Biochem. Pharmacol. 26 1977 1039 1042
10. K. Richardson The discovery of fluconazole Drug News Perspect. 6 1993 299 303
11. Hutzler Inhibition of cytochrome P450 3A4 by a pyrimidineimidazole: evidence for complex heme interactions Chem. Res. Toxicol. 19 2006 1650 1659
12. R.B. Silverman Mechanism-based enzyme inactivation D.L. Purich, Contemporary Enzyme Kinetics and Mechanisms 2nd edn 1996 Academic Press 291 335
13. M.A. Correia, and P.R. Ortiz de Montellano Inhibition of cytochrome P450 enzymes Cytochrome P450: Structure, Mechanism and Biochemistry 2005 Kluwer Academic/Plenum Publishers pp. 247-322
14. J.R. Halpert Identification of selective mechanism-based inactivators of cytochromes P-450 2B4 and 2B5, and determination of the molecular basis for differential susceptibility J. Pharm. Exp. Ther. 290 1999 445 451
15. M. Shou A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4 J. Biol. Chem. 276 2001 2256 2262
16. S.M. Poli Irreversible cytochrome P450 inhibition: common substructures and implications for drug development Antitargets: Prediction and Prevention of Drug Side Effects 2008 Wiley-VCH Verlag GmbH & Co. pp. 267-276 (Chapter 11)
17. A.F. Stepan Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States Chem. Res. Toxicol. 24 2011 1345 1410
18. A.S. Kalgutkar Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions Curr. Drug Metab. 8 2007 407 447
19. S.M. Poli Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity Curr. Drug Metab. 6 2005 413 454
20. Obach Inactivation of human cytochrome P450 enzymes and drug-drug interactions Enzyme- and Transporter-Based Drug-Drug Interactions 2010 Springer for Research and Development pp. 473-495 (Chapter 19, Part 3)
21. L. Leung Metabolic activation in drug-induced liver injury Drug Metab. Rev. 44 2012 18 33
22. Trager The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome p450-catalyzed reactions, and mechanisms of metabolically dependent toxicity Drug Metab. Dispos. 31 2003 1481 1498
23. Kamel Deuterated drug approach to mitigate formation of reactive metabolites during drug discovery Mitigation Strategies for Reactive Metabolites Boston, MA 2011
24. CoNECERT Pharmaceutical Inc. press release http://www.concertpharma.com/ news/press-releases.html
25. D.J. McConn Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs Drug Metab. Dispos. 32 2004 1083 1091
26. G.F. Reidy Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P450 and inhibition kinetics Mol. Pharmacol. 35 1989 736 743
27. J.P. Mahy Iron porphyrin-nitrene complexes: preparation from 1,1-dialkylhydrazines: electronic structure from NMR, Mössbauer, and the magnetic susceptibility studies and crystal structure of the [tetrakis(p-chlorophenyl) porphyrinato-(2,2,6,6,-tetramethyl-1-piperidyl) nitrene] iron complex J. Am. Chem. Soc. 106 1984 1699 1706
28. S.F. Muakkasah Mechanism of the inhibitory action of isoniazid on microsomal drug metabolism Biochem. Pharmacol. 30 1981 1651 1658
29. A.P. Li A review of the common properties of drugs with idiosyncratic hepatotoxicity and the 'multiple determinant hypothesis' for the manifestation of idiosyncratic drug toxicity Chem. Biol. Interact. 142 2002 7 23
30. P.R. Ortiz de Montellano Suicide substrate for drug metabolizing enzymes: mechanisms and biological consequences G.G. Gibson, Progress in Drug Metabolism Vol. 11 1988 Taylor & Francis 99 148
31. J.F. Rusling Screening for reactive metabolites using genotoxicity arrays and enzyme/DNA biocolloids P.F. Hollenberg, J. Scatina, A.F. Nassar, Drug Metabolism Handbook: Concepts and Applications 2009 Copyright © 2009 by John Wiley & Sons, Inc. 307 340 (Chapter 13)
32. F.P. Guengerich Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene Chem. Res. Toxicol. 3 1990 363 371
33. P.R. Ortiz De Montellano Branchpoint for heme alkylation and metabolite formation in the oxidation of arylacetylenes by cytochrome P-450 J. Biol. Chem. 260 1985 3330 3336
34. P.R. Ortiz De Montellano 'Self-catalyzed inactivation of hepatic cytochrome P450 by ethynyl substrates' Paul R. Ortiz de Montellano, et al. J. Biol. Chem. 255 1980 5578
35. F.J. Gonzalez The 2006 Bernard B. Brodie Award Lecture. CYP2E1 Drug Metab. Dispos. 35 2007 1 8
36. Eneli, I. et al. Acetaminophen and the Risk of Asthma: The Epidemiologic and Pathophysiologic Evidence: http://chestjournal.chestpubs.org/content/127/2/ 604.full.html
37. G.S. Yost Mechanisms of 3-methylindole pneumotoxicity Chem. Res. Toxicol. 2 1989 273 279
38. N.P.E. Vermeulen Cytochrome P450 in silico: an integrative modeling approach J. Med. Chem. 48 2005 2725 2755
39. M.J. De Groot Designing better drugs: predicting cytochrome P450 metabolism Drug Discov. Today 11 2006 601 606
40. S. Ekins Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug metabolism and disposition Drug Metab. Dispos. 29 2001 936 944
41. S. Ekins Three and four dimensional-quantitative structure activity relationship analyses of CYP3A4 inhibitors J. Pharm. Exp. Ther. 290 1999 429 438
42. S. Ekins Development of computational models for enzymes, transporters, channels and receptors relevant to ADME/TOX Rev. Comp. Chem. 20 2004 333 415
43. Erve Characterization of glutathione conjugates of duloxetine by mass spectrometry and evaluation of in silico approaches to rationalize the site of conjugation for thiophene containing drugs Chem. Res. Toxicol. 23 2010 1393 1404
44. H. Li Considerations and recent advances in QSAR models for cytochrome P450-mediated drug metabolism prediction J. Comput. Aided Mol. Des. 22 2008 843 855